DelphiAdvisorSoon
Pharmaceuticals: Major · #84 in the Retail 100

AbbVie

ABBV
$286.00
+$53.94 (+23.24%)Past year

About the company

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

CEO
Robert A. Michael
Sector
Health Technology
Market value
$505.34B
Price / earnings
49.6x

No takeaway or recommendation for AbbVie yet. It is #3 in line. We add companies in batches of about 10, in Retail 100 order.

Next earnings

Next earnings report
Feb 3
In 90 days
Expected earnings per share
$3.90
Expected revenue
$18.33B

Last earnings

Reported Oct 30ExpectedActualDifference
Earnings per share$3.73$3.82+2.4%
Revenue$17.32B$17.40B+0.5%